Abstract
As renal function declines, the prevalence of both malnutrition and cardiovascular disease increase. Both malnutrition and vascular disease correlate with the levels of markers of inflammation both in patients treated with dialysis and in those not yet on dialysis. While it is possible that the markers of inflammation (increased levels of C-reactive protein (CRP) or interleukin-6 (IL-6)) are a result of inflammation arising from the atherosclerotic process, changes in endothelial cell gene expression, in plasma protein composition and in lipoprotein structure that arise from inflammation are likely to be atherogenic. The causes of inflammation are likely to be multifactorial. CRP levels are associated with cardiovascular risk in the general population and decrease following treatment with HMG-CoA reductase inhibitors. It is speculated that use of these agents or directly suppressing inflammation may have use in treating the inflammatory-malnutrition syndrome in dialysis patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 70-80 |
| Number of pages | 11 |
| Journal | Blood Purification |
| Volume | 20 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2002 |
| Externally published | Yes |
Fingerprint
Keywords
- Albumin
- C-reactive protein
- Cytokines
- Inflammation
- Interleukin-6
- Nutrition
- Prealbumin
ASJC Scopus subject areas
- Nephrology
- Hematology
Cite this
Role of inflammation and its treatment in esrd patients. / Kaysen, George.
In: Blood Purification, Vol. 20, No. 1, 2002, p. 70-80.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Role of inflammation and its treatment in esrd patients
AU - Kaysen, George
PY - 2002
Y1 - 2002
N2 - As renal function declines, the prevalence of both malnutrition and cardiovascular disease increase. Both malnutrition and vascular disease correlate with the levels of markers of inflammation both in patients treated with dialysis and in those not yet on dialysis. While it is possible that the markers of inflammation (increased levels of C-reactive protein (CRP) or interleukin-6 (IL-6)) are a result of inflammation arising from the atherosclerotic process, changes in endothelial cell gene expression, in plasma protein composition and in lipoprotein structure that arise from inflammation are likely to be atherogenic. The causes of inflammation are likely to be multifactorial. CRP levels are associated with cardiovascular risk in the general population and decrease following treatment with HMG-CoA reductase inhibitors. It is speculated that use of these agents or directly suppressing inflammation may have use in treating the inflammatory-malnutrition syndrome in dialysis patients.
AB - As renal function declines, the prevalence of both malnutrition and cardiovascular disease increase. Both malnutrition and vascular disease correlate with the levels of markers of inflammation both in patients treated with dialysis and in those not yet on dialysis. While it is possible that the markers of inflammation (increased levels of C-reactive protein (CRP) or interleukin-6 (IL-6)) are a result of inflammation arising from the atherosclerotic process, changes in endothelial cell gene expression, in plasma protein composition and in lipoprotein structure that arise from inflammation are likely to be atherogenic. The causes of inflammation are likely to be multifactorial. CRP levels are associated with cardiovascular risk in the general population and decrease following treatment with HMG-CoA reductase inhibitors. It is speculated that use of these agents or directly suppressing inflammation may have use in treating the inflammatory-malnutrition syndrome in dialysis patients.
KW - Albumin
KW - C-reactive protein
KW - Cytokines
KW - Inflammation
KW - Interleukin-6
KW - Nutrition
KW - Prealbumin
UR - http://www.scopus.com/inward/record.url?scp=0036007326&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036007326&partnerID=8YFLogxK
U2 - 10.1159/000046988
DO - 10.1159/000046988
M3 - Article
C2 - 11803162
AN - SCOPUS:0036007326
VL - 20
SP - 70
EP - 80
JO - Blood Purification
JF - Blood Purification
SN - 0253-5068
IS - 1
ER -